Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy
Via, J. D., Daly, R. M., Owen, P. J., Mundell, N. L., Rantalainen, T., & Fraser, S. F. (2019). Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy. Bone, 127, 367-375. https://doi.org/10.1016/j.bone.2019.06.005
Published in
BoneAuthors
Date
2019Discipline
BiomekaniikkaGerontologian tutkimuskeskusHyvinvoinnin tutkimuksen yhteisöBiomechanicsGerontology Research CenterSchool of WellbeingCopyright
© 2019 Elsevier Inc
Androgen deprivation therapy (ADT) improves survival in men with advanced prostate cancer (PCa), but has been associated with compromised skeletal health and increased fracture risk. However, limited previous research has investigated determinants of bone strength beyond DXA-derived areal bone mineral density (aBMD) in this population group. The aim of this cross-sectional study was to investigate the effects of ADT in men with PCa on BMD, bone structure, estimates of whole bone strength and cortical bone distribution. A total of 70 ADT-treated men, 52 PCa controls and 70 healthy controls had DXA lumbar spine and proximal femur aBMD and pQCT distal (4%) and proximal (66%) tibia and radius cortical and trabecular volumetric BMD (vBMD), bone structure, strength and cortical bone distribution assessed. Analyses included BMI and/or tibia/radius length as covariates. On average, ADT-treated men had a higher BMI than PCa (P < 0.05) but not healthy controls. ADT-treated men had 7.2–7.8% lower lumbar spine aBMD than PCa (P = 0.037) and healthy controls (P = 0.010), with a trend for a lower total hip aBMD in the ADT-treated men (P = 0.07). At the distal tibia, total bone area was 6.2–7.3% greater in ADT-treated men than both controls (P < 0.01), but total vBMD was 8.4–8.7% lower in ADT-treated men than both controls (P < 0.01). Moreover, bone strength index (BSI) was 10.8% lower relative to healthy controls only (P < 0.05). At the distal radius, ADT-treated men had lower total and trabecular vBMD (10.7–14.8%, P < 0.05) and BSI (23.6–27.5%, P < 0.001) compared to both controls. There were no other differences in bone outcomes at the proximal tibia or radius. In conclusion, ADT treatment for PCa was associated with lower BMD and estimated compressive bone strength, particularly at trabecular skeletal sites (lumbar spine, and distal tibia and radius), compared to controls, but there were no consistent differences in cortical bone structure, distribution or bending strength.
...
Publisher
Elsevier Inc.ISSN Search the Publication Forum
8756-3282Keywords
Publication in research information system
https://converis.jyu.fi/converis/portal/detail/Publication/30939592
Metadata
Show full item recordCollections
- Liikuntatieteiden tiedekunta [3164]
Additional information about funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.License
Related items
Showing items with similar title or keywords.
-
Musculoskeletal Responses to Exercise plus Nutrition in Men with Prostate Cancer on Androgen Deprivation : A 12-month RCT
Via, Jack Dalla; Owen, Patrick J.; Daly, Robin M.; Mundell, Niamh L.; Livingston, Patricia M.; Rantalainen, Timo; Foulkes, Stephen J.; Millar, Jeremy L.; Murphy, Declan G.; Fraser, Steve F. (Lippincott Williams & Wilkins, 2021)Purpose Androgen deprivation therapy (ADT) for prostate cancer (PCa) has multiple adverse effects on musculoskeletal health. This 12-month randomised controlled trial aimed to assess the effects of multi-component exercise ... -
Supervised Physical Training Enhances Muscle Strength but Not Muscle Mass in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy : A Systematic Review and Meta-Analysis
Chen, Ziyuan; Zhang, Yuan; Lu, Chunyan; Zeng, Hao; Schumann, Moritz; Cheng, Sulin (Frontiers Media, 2019)Introduction: Androgen deprivation therapy (ADT) is considered the basic treatment for advanced prostate cancer, but it is highly associated with detrimental changes in muscle mass and muscle strength. The aim of this ... -
The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer
Owen, Patrick J.; Daly, Robin M.; Via, Jack Dalla; Mundell, Niamh L.; Livingston, Patricia M.; Rantalainen, Timo; Fraser, Steve F. (Wiley - VCH Verlag GmbH & Co. KGaA, 2019)Background: Androgen deprivation therapy (ADT) for prostate cancer (PCa) may prospectively decrease absolute lean mass (LM) and increase absolute fat mass (FM). Given that estimates of LM by dual‐energy X‐ray absorptiometry ... -
Radiotherapy before or during androgen-deprivation therapy does not blunt the exercise-induced body composition protective effects in prostate cancer patients : A secondary analysis of two randomized controlled trials
Newton, Robert U.; Mavropalias, Georgios; Fragala, Maren S.; Kraemer, William J.; Häkkinen, Keijo; Taaffe, Dennis R.; Spry, Nigel; Joseph, David; Galvão, Daniel A. (Elsevier, 2021)Background Androgen deprivation therapy (ADT) contributes to lean mass loss and adiposity increases in prostate cancer patients. Radiotherapy during ADT might act synergistically and further worsen body composition. ... -
Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?
Owen, Patrick J.; Daly, Robin M.; Dalla Via, Jack; Mundell, Niamh L.; Livingston, Patricia M.; Rantalainen, Timo; Fraser, Steve F. (Springer New York LLC, 2019)Androgen deprivation therapy (ADT) for prostate cancer (PCa) can compromise muscle health. Hence, we aimed to quantify the prevalence of sarcopenia (i.e., compromised lean mass, muscle strength, and physical function) in ...